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Abstract. Previously, we showed that the encapsulation and release properties of a liposomal ciprofloxacin
formulation could be modified post manufacture, by addition of surfactant in concert with osmotic
swelling of the liposomes. This strategy may provide more flexibility and convenience than the alternative
of manufacturing multiple batches of liposomes differing in composition to cover a wide range of release
profiles. The goal of this study was to develop a surfactant-associated liposomal ciprofloxacin (CFI)
formulation possessing good long-term stability which could be delivered as an inhaled aerosol. Prepara-
tions of 12.5 mg/ml CFI containing 0.4% polysorbate 20 were formulated between pH 4.7 and 5.5. These
formulations, before and after mesh nebulization, and after refrigerated storage for up to 2years, were
characterized in terms of liposome structure by cryogenic transmission electron microscopy (cryo-TEM)
imaging, vesicle size by dynamic light scattering, pH, drug encapsulation by centrifugation-filtration, and
in vitro release (IVR) performance. Within the narrower pH range of 4.9 to 5.2, these formulations
retained their physicochemical stability after 2-year refrigerated storage, were robust to mesh nebuliza-
tion, and formed respirable aerosols with a volume mean diameter (VMD) of 3.7 μm and a geometric
standard deviation (GSD) of 1.7. This study demonstrates that it may be possible to provide a range of
release profiles by simple addition of surfactant to a liposomal formulation post manufacture, and that
these formulations may retain their physicochemical properties after long-term refrigerated storage and
following aerosolization by mesh nebulizer.
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INTRODUCTION
Liposomes represent a versatile formulation and delivery
technology that can be used to modulate a drug’s pharmaco-
kinetic profile with the potential to improve both the safety
and efficacy of treatment (1,2). Liposomal formulations are
now well-accepted with more than ten liposomal pharmaceu-
tical products approved to treat a variety of indications as
diverse as fungal infection, ovarian cancer, myeloma, macular
degeneration, and leukemia (2,3). The physicochemical and
release properties can be designed into the liposomal formu-
lation through appropriate selection of a number of variables
including the lipid and sterol composition, the ratio of sterol to
lipid, the addition of surface-modifying groups (e.g., polyeth-
ylene glycol), the size and lamellarity of the liposomes, the
method of drug loading, the state of the drug inside the
liposomes, and the ratio of drug to lipid (1,4,5).
Generally, once a liposome formulation has been
manufactured, its drug release properties are not typically
modifiable. Thus, in order to provide personalized therapy
to individuals, who may optimally respond to distinct drug
release profiles, multiple batches of liposomes would have to
be manufactured possessing different release kinetics. Be-
cause of the complexity and expense of this approach, from
both a manufacturing and regulatory perspective, none of the
currently marketed liposomal products come in multiple for-
mats each with its own unique release behavior. A simple and
flexible approach which allows modification of the drug re-
lease rate of a single liposomal formulation post manufacture,
could address this issue.
In a previous study, we demonstrated that the encapsula-
tion and drug release properties of a liposomal ciprofloxacin
formulation could be altered by addition of surfactant in com-
bination with osmotic swelling of the liposome (6). In absence
of osmotic swelling, the surfactant caused only a small change
in the drug encapsulation state (~6% loss of encapsulated
drug for 12.5 mg/mL CFI mixed with 0.4% polysorbate 20)
and there was no change in the IVR profile (6). In contrast, for
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12.5 mg/mL CFI mixed with 0.4% polysorbate 20 under hy-
potonic conditions, the drug encapsulation state decreased by
~30% and this formulation also had a much faster IVR profile
than the unmodified formulation (6). In the present study, we
were interested whether surfactant-associated liposome for-
mulations could be designed to retain their physicochemical
properties under long-term refrigerated storage and following
aerosol delivery using nebulizers.
Currently, there are no liposomal formulations approved
for delivery by the inhalation route. However, the potential
for liposomal formulations of drugs to be used to treat lung
disease has been intensively investigated, both in terms of
understanding the in vitro requirements and the medical op-
portunities (2,3,7,8). A marketed liposomal formulation of
amphotericin B has been used off-label in lung transplant
patients as a prophylaxis to prevent fungal infections and
was found to be better tolerated than formulations of free
amphotericin B (3). Repeated inhalation of amphotericin
B liposomes also did not appear to alter the composition
of the lipid and surfactant pool in the lungs, nor were
there any changes in lung function, suggesting an accept-
able safety profile (9). Two inhaled liposomal antibiotic
formulations are now in late stages of clinical develop-
ment to treat lung infection (2,10).
Inhaled ARIKACE®, liposomal amikacin (Insmed,
Monmouth Junction, NJ), in cystic fibrosis (CF) patients, was
found to reduce Pseudomonas aeruginosa (PA) colonization
and improve lung function at the end of each of the six 28-day
treatment cycles (11). In a Phase 3 trial in CF patients de-
signed to support regulatory filing in Europe and Canada,
once-daily ARIKACE met the primary endpoint of non-infe-
riority to inhaled tobramycin solution dosed twice-daily (12).
Inhaled ARIKACE is also being evaluated in a Phase 2 trial in
90 patients with nontuberculous mycobacteria (NTM) lung
infections and enrollment was recently completed; the primary
efficacy data of change in mycobacteria density are expected
to be reviewed and released to the FDA before the end of Q1,
2014. Pulmaquin® (Aradigm Corporation, Hayward, CA),
a dual release formulation of liposomal ciprofloxacin and
unencapsulated ciprofloxacin with an in vivo half-life of
~10 h, achieved the primary and a secondary measure of
efficacy in a Phase 2 trial in non-CF bronchiectasis and
has cleared a US IND to enter Phase 3 trials in that
indication (13).
In addition to meeting all specification criteria typical for
pharmaceutical products, including those used to verify
strength, quality, purity, and potency of the product, liposomal
formulations intended for inhalation should also be robust to
the aerosolization process (2). Most inhaled liposomal formu-
lations have been developed for use with nebulizers but the
nebulization process often compromises the state of drug
encapsulation or modifies the vesicle size distribution (2).
The presence of surfactant in the liposome formulation may
serve to exacerbate this tendency for disruption by nebuliza-
tion. In fact, a liposome formulation containing polysorbate 80
to increase its deformability was found to be unstable to jet,
ultrasonic, and vibrating mesh nebulization with release of up
to 98% of the encapsulated salbutamol sulfate drug (14).
Thus, it might be expected that surfactant-modified liposome
formulations, with altered encapsulation and release profiles,
may be inherently unstable to the nebulization process. Thus,
the selected formulations were placed on long-term stability
and also evaluated for their stability in response to mesh
nebulization. Jet nebulizers were also evaluated but rejected
because the presence of surfactant caused excessive foaming
in those devices. The goal of this study was to identify surfac-
tant-associated liposome formulations that retained their
physicochemical properties on stability and following mesh
nebulization. This research is consistent with the overarching
mission of personalized medicine by developing a simple
methodology, addition of surfactant, to modify the release
properties of an inhaled liposomal formulation.
MATERIALS AND METHODS
Materials
Lipoquin, liposomal ciprofloxacin (CFI), 50 mg/ml in a
histidine-buffered aqueous formulation at pH 6.0 and free
ciprofloxacin (FCI), 20 mg/ml, in an acetate-buffered aqueous
formulation at pH 3.3 were from Aradigm Corporation (Hay-
ward, CA). Nanosep centrifugal filtration devices, 10 K and
30 K molecular weight, were obtained from Pall Corporation
(Ann Arbor, MI). Deionized water was used for all studies.
Polysorbate 20 was purchased from VWR Int. (West Chester,
NJ) while HEPES, free acid was purchased from Avantor
(Center Valley, PA). Sodium chloride and sodium acetate
were obtained from Amresco (Solon, OH) and Sigma-Aldrich
(St. Louis, MO), respectively. HPLC grade methanol was
purchased from Fisher Scientific (Fair Lawn, NJ) and
Triethylamine (TEA) and HPLC grade methanol were ob-
tained from HyClone (Logan, Utah) and JT Baker (Center
Valley, Pennsylvania), respectively.
Preparation of Liposomal Ciprofloxacin
Lipoquin is an aqueous dispersion of unilamellar lipo-
somes of ~80 nm containing hydrogenated soy phosphatidyl-
choline (HSPC) and cholesterol. The preparation of Lipoquin,
liposomal ciprofloxacin (CFI), has been reported previously
(15,16). Briefly, multilamellar liposomes are extruded through
membranes to produce unilamellar liposomes which are then
ac t ive ly loaded wi th c iprof loxac in (17 ,18) . Any
unencapsulated ciprofloxacin is removed by diafiltration
resulting in >99% encapsulated ciprofloxacin at a target con-
centration of 50 mg/ml ciprofloxacin. Pulmaquin, dual release
ciprofloxacin for inhalation (DRCFI), is an equivolume mix-
ture of FCI and CFI resulting in ~70% encapsulated and
~30% free ciprofloxacin.
Preparation and Selection of CFI Formulations for Long-
Term Stability
CFI was diluted from 50 mg/ml to 12.5 mg/ml with water,
sodium acetate buffer (25 mM sodium acetate, 145 mM NaCl,
pH 4.0), and polysorbate 20, to achieve a final polysorbate 20
concentration of 0.4% (w/v). The target pH was 5.5 (for the
unadjusted formulation), and 5.2, 4.9, and 4.7 for the three pH
adjusted formulations, by varying the proportion of water or
sodium acetate buffer that was added. These four formula-
tions containing 12.5 mg/ml CFI, 0.4% polysorbate 20, but
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differing in pH and osmolarity, were stored at refrigerated con-
ditions for evaluation of long-term stability. Fifty milliliters of
each formulationwas prepared and ~6ml aliquots were pipetted
into eight 10 ml glass vials and stored at 2–8°C until use. At
various time points, including initial, 1 month, 2.5 months,
6 months, 1 year, and 2 years, vials were removed for analysis
of their appearance, pH, vesicle size distribution, and drug
encapsulation. The IVR profile was determined at the initial,
6-month and 1-year time points. The aerosol properties were
determined at the initial, 1-month, and 6-month time points.
Aerosol Characterization
The aerosol particle size distribution of the 12.5 mg/ml
CFI formulation containing 0.4% polysorbate 20, pH 5.5 was
determined using laser diffraction (HELOS/BF, Sympatec
GmbH, Clausthal-Zellerfeld, Germany). The aerosol output
was drawn at 12.5 L/min through a flow-through cell in front
of the optical lens and twenty time slices of 500 μs each were
analyzed. WINDOX 5 software was used assuming a shape
factor of 1.00, density of 1.019 g/cm3, andMie analysis mode to
calculate a volume mean diameter (VMD) and geometric
standard deviation (GSD).
At the initial time point, 5 ml aliquots of the control CFI
formulation and the pH 5.5, 4.9, and 4.7 CFI formulations
containing 0.4% polysorbate 20 were loaded into the Pari
eFlow® rapid nebulizer reservoir (Pari Pharma, Starnberg,
Germany) with a 4-μm mesh, the nebulizer was turned on,
and the aerosol output was collected in an SKC BioSampler
(USA) containing 5 ml of 25 mM acetate buffer, pH 4.0. The
nebulization time and mass of liposomal ciprofloxacin in the
nebulizer residual and collected aerosol compartments were
determined in each of the duplicate experiments. The mean
vesicle size and state of encapsulation were determined before
nebulization and after nebulization for the formulation recov-
ered in the nebulizer reservoir and the collected aerosol. In
subsequent characterization experiments at the 1-month and
6-month time points, the aerosol evaluation was performed on
the formulation which accumulated in the device mouthpiece,
rather than drawing the aerosol into the SKC Biosampler, as it
was suspected that the collection in the Biosampler could
modify the vesicle size. The sample from the mouthpiece
represented impaction of droplets that had passed through
the mesh and were exposed to the aerosolization process.
For the 1-month and 6-month time points, both the vesicle
size and encapsulation state were additionally measured. The
IVR profiles of the aerosolized samples were characterized at
the 6-month time point only.
pH
A Beckman Phi690 pH Meter (Fullerton, CA) with a
Beckman Coulter combination pH electrode, Model 511275
(Fullerton, CA), was calibrated using Fisher (Fairlawn, NJ)
pH 4.00 and 6.00 buffer standards and then used to measure
the pH of the experimental samples.
Vesicle Size
To measure the liposome size distribution of each exper-
imental CFI sample, a Submicron Particle Sizer Autodilute
Model 370 (Nicomp, USA) was used. Each CFI sample was
diluted with isotonic saline to a concentration of ~2 mg/ml
liposomes and 0.5 ml was transferred to a disposable culture
tube (Kimble Glass Inc., USA). The mean and standard devi-
ation (SD) of the vesicle size distribution were recorded using
the following instrument parameters: temperature, 23°C; vis-
cosity, 0.933; refractive index, 1.333; intensity set point,
300 KHz; channel width, 10 μs; scattering angle, 90°; run time,
5 min; mode, vesicle; and Gaussian distribution.
Drug Encapsulation
The percent drug encapsulation was determined by sep-
arating the free drug from the encapsulated drug using
Nanosep centrifugation devices. Briefly, each sample was di-
luted tenfold into acetate buffer (50 mM sodium acetate,
145 mM NaCl, pH 4.0) and 400 μL was transferred to the
centrifuge device and centrifuged at 10,000 rpm (8,100×g).
The filtrate containing the free ciprofloxacin component was
analyzed by HPLC to measure ciprofloxacin content. The
percent encapsulation of each sample was calculated by divid-
ing the free drug component by the total drug content and
multiplying by 100 to convert to a percentage.
Cryogenic Transition Electron Microscopy (cryo-TEM)
Cryo-TEM analysis was performed using a JEOL 2100
(Tokyo, Japan) instrument operated at 200 kV to image the
liposome vesicles. Each sample was diluted with water to a
liposome concentration of ~10 mg/ml lipids and 3 μL was
transferred to a glow discharge Quantifoil carbon grid (Jena,
Germany) in a chamber equilibrated at 22°C and 100% RH.
Grids were blotted once with filter paper, at a blotting angle of
2 mm for 2 s, and vitrified by plunging into liquid ethane using
a Vitrobot (F.E.I., Eindhoven, Netherlands). To ensure sam-
ple integrity prior to cryo-TEM analysis, the vitrified samples
remained immersed in liquid nitrogen.
In Vitro Release (IVR)
The IVR assay measures the release of encapsulated
ciprofloxacin when incubated at 37°C in 50% bovine serum
(16). Briefly, each experimental sample was diluted to 50 μg/
ml ciprofloxacin in HEPES Buffered Saline (HBS, 20 mM
HEPES; 145 mM NaCl, pH 7.4) and mixed one-to-one with
chilled (2–8°C) bovine serum and placed in a shaking water
bath (Techne, TSBS40 (Staffordshire, UK)) at 37°C and
150 rpm. Duplicate samples were removed periodically; e.g.,
30, 60, 120, and 240 min, diluted 1:1 with chilled HBS buffer,
and placed in an ice water bath to terminate any further
release of encapsulated drug from the liposomes. The released
ciprofloxacin was separated from the liposome-encapsulated
ciprofloxacin using the Nanosep centrifugal devices and quan-
tified by HPLC as described previously (16). The percent
release at each time point was determined by dividing the free
drug by the total drug and multiplying by 100 to convert to a
percentage. In order to compare the initial release rates of
different formulations with different percentages of encapsu-
lated drug, a normalized initial rate of release was calculated.
This was done by subtracting the percentage of drug released
initially from that released at the 30 min time point; i.e.,
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(T30min−T0min). This initial release value was then divided by
the total available range for release (T240min−T0min) and con-
verted to a percentage: 100×(T30min−T0min)/(T240min−T0min).
High Performance Liquid Chromatography (HPLC)
An HPLC method was used to quantify the amount of
ciprofloxacin in each sample as described previously (19).
Briefly, this was achieved using a Nucleosil C-18 column
(5 μm, 4.6×150 mm, Canadian Life Science, CA) and a
Nucleosil C-18 guard column (4×3.0 mm, Phenomenex,
USA) both at 35°C. The mobile phase was an 83:17 (v/v)
mixture of 0.5% TEA in water, pH 3.0 and 100% methanol.
The isocratic elution was conducted at a flow rate was 0.9 ml/
min. A wavelength of 277 nm was used to quantify ciproflox-
acin content. Ciprofloxacin concentrations were expressed in
terms of ciprofloxacin hydrochloride.
RESULTS
Selection of CFI Formulations for Long-Term Stability
Dilution of 50 mg/mL CFI to 12.5 mg/mL with polysor-
bate 20 and water, instead of histidine buffer, to produce a
hypotonic environment surrounding the liposomes, resulted in
much greater release of the encapsulated ciprofloxacin
(Fig. 1). Polysorbate 20 when added to CFI in a hypotonic
environment at a concentration between 0.4 and 1.6%, caused
~30 to 40% of the encapsulated ciprofloxacin to be released
from the liposomes, versus only ~6 to 8% release when the
surfactant was added to CFI under isotonic conditions (Fig. 1).
The combination of osmotic swelling of the liposomes, in
concert with surfactant, allowed for more of the encapsulated
drug to be released (6). In addition, the 12.5 mg/mL CFI
formulation containing 0.4% polysorbate 20 when prepared
in a hypotonic environment also possessed a faster release
rate in the IVR assay, whereas lower concentrations of poly-
sorbate 20 did not significantly alter the release rate (Fig. 2a).
The CFI formulation containing 0.4% polysorbate 20 was
compared to DRCFI, which is a ~70:30 mixture of CFI and
unencapsulated ciprofloxacin, in the IVR assay and both pos-
sessed a comparable “burst” value of ~30%, but the surfac-
tant-modified CFI formulation had a faster release profile
than DRCFI (Fig. 2a). After 2 to 4 h incubation in the IVR
assay, all formulations released nearly 100% of the encapsu-
lated drug (Fig. 2a).
Based on these results, the 12.5 mg/mL CFI formulation
containing 0.4% polysorbate 20 added under hypotonic con-
ditions was selected for further studies for its potential as an
inhaled product. However, because ciprofloxacin is poorly
soluble near neutral pH, this unbuffered formulation was not
expected to possess good long-term stability. In fact, rod-
shaped crystals of ciprofloxacin were observed external to
the liposomes under light microscope within 48 h of addition
of the surfactant when the pH was not adjusted from pH 5.5.
In order to develop a formulation with acceptable long-term
stability, the 50 mg/ml CFI formulation was diluted with poly-
sorbate 20, sodium acetate buffer, and water to produce
12.5 mg/mL CFI formulations containing 0.4% polysorbate
20 and pH values of 5.2, 4.9, and 4.7. These formulations were
stored refrigerated for periodic evaluation of appearance,
vesicle size distribution, ciprofloxacin encapsulation, pH, and
IVR profile.
Long-Term Stability
Appearance, Vesicle Size, and pH
The visual appearance of the pH 4.7 and 4.9 CFI formu-
lations containing 0.4% polysorbate 20 remained particle-free
throughout the 2-year study while a small number of fine
particles were observed in the pH 5.2 formulation at the 2.5,
6, 12, and 24-month time points. Presumably, the small parti-
cles were fine crystals of ciprofloxacin external to the lipo-
somes. The mean liposome vesicle size ranged between 89 and
100 nm across all four formulations through the 2-year time
point (Table I). There was no meaningful change in vesicle
size for any of the three formulations during the 1-year study.
The pH was relatively unchanged for the pH 4.7, 4.9, and 5.2
CFI formulations containing 0.4% polysorbate 20 through 2
years (Table II).
Encapsulation
The encapsulation of the 50 mg/mL CFI control sample
remained at ~99% over the 24-month period (Table III). The
12.5 mg/ml CFI formulation at pH 5.5 containing 0.4% poly-
sorbate 20 had between 70 and 75% drug encapsulation ini-
tially, but these samples were not monitored on stability due to
crystallization of the released ciprofloxacin. For the pH ad-
justed formulations, the initial percent encapsulation de-
creased from 99% to ~80, ~85, and ~92% when diluted with
sodium acetate buffer and water to lower the pH to 5.2, 4.9,
and 4.7, respectively (Table III). The more acetate buffer that
was used to reduce the pH correlated with higher starting
encapsulation values, consistent with the mechanism that
Fig. 1. The effect of addition of polysorbate 20 on the state of ciproflox-
acin encapsulation when diluted with either water or isotonic histidine
buffer, pH 6.0 buffer. CFI at 50 mg/ml ciprofloxacin was diluted to a final
concentration of ~12.5 mg/ml with water or histidine buffer and then
either an aliquot of 1 or 10% polysorbate 20 was added to achieve a final
surfactant concentration of 0.1, 0.2, 0.4, 0.8, 1.2, 1.6, or 2.0%. After
vortexing and allowing each sample to equilibrate for at least 30 min,
the ciprofloxacin encapsulation state was determined by centrifugal
filtration in duplicate. Adapted from reference (6)
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release of encapsulated drug occurs to a greater extent under
hypotonic conditions (6). These encapsulation values
remained fairly constant over the 2-year refrigerated storage
period (Table III).
IVR Profiles
The IVR profiles of the three CFI formulations with ad-
justed pH values show similar characteristics to the IVR profile
for the pH 5.5 formulation without pHmodification at the initial
time point (Fig. 2b). The IVR “burst” values ranged between 12
and 27% free drug for the four formulations prior to incubation
at 37°C. The formulation with the lowest pH (pH 4.7) contained
the greatest encapsulated drug (88%) and lowest free drug
(12%) while the unmodified formulation at the highest pH
(pH 5.5) had the lowest encapsulated drug (73%) and highest
free drug (27%) in the IVR assay. These IVR “burst” values are
comparable to the encapsulation values reported in Table III, as
would be expected. The IVR profiles for the CFI formulations
containing 0.4% polysorbate 20 at pH 4.9, 5.2, and 5.5 were
Fig. 2. Evaluation of the effect of liposomal composition on the IVR assay. The control CFI formulation (at 50 mg/mL) and each of the 12.5 mg/
mL CFI formulations were diluted to 50 μg/mL CFI in HEPES buffered saline (HBS) prior to a 1:1 dilution in bovine serum to measure the
release of ciprofloxacin after incubation at 37°C for up to 4 h. a IVR profiles for control CFI (blue diamonds), DRCFI (orange circles), CFI in
0.05% polysorbate 20 (purple crosses), CFI in 0.1% polysorbate 20 (green triangles), CFI in 0.2% polysorbate 20 (blue stars), and CFI in 0.4%
polysorbate 20 (red squares). Fig. 2a reprinted with permission from reference 6. b IVR profiles at the initial time point for control CFI (blue
diamonds), CFI in 0.4% polysorbate 20, pH 5.5 (purple crosses), CFI in 0.4% polysorbate 20, pH 5.2 (green triangles), CFI in 0.4% polysorbate
20, pH 4.9 (blue stars), and CFI in 0.4% polysorbate 20, pH 4.7 (red squares). c IVR profiles at the 6-month time point for control CFI (blue
diamonds), CFI in 0.4% polysorbate 20, pH 5.2 (green triangles), CFI in 0.4% polysorbate 20, pH 4.9 (blue stars), and CFI in 0.4% polysorbate
20, pH 4.7 (red squares). d IVR profiles at the 12-month time point for control CFI (blue diamonds), CFI in 0.4% polysorbate 20, pH 5.2 (green
triangles), 12.5 mg/ml CFI in 0.4% polysorbate 20, pH 4.9 (blue stars), and 12.5 mg/ml CFI in 0.4% polysorbate 20, pH 4.7 (red squares). e IVR
profiles at the 6-month time point after nebulization for the nebulizer residual solution (Neb Res) and collected aerosol, respectively: CFI in
0.4% polysorbate 20, pH 5.2 (blue diamonds and purple crosses), CFI in 0.4% polysorbate 20, pH 4.9 (green triangles and blue stars), and CFI in
0.4% polysorbate 20, pH 4.7 (red squares and orange circles). Each value represents the mean±SD (n=3 or 2). The error bars which are not
visible are smaller than the width of the data symbols
Table I. The Vesicle Size Distribution of the CFI Control and the pH Adjusted 12.5 mg/ml CFI Formulations Containing 0.4% Polysorbate 20
After Refrigerated Storage for 2.5, 6, 12 and 24 Months. Vesicle Size Data are Reported as the Mean (in nm) and [SD]
Time (months) CFI control pH 5.2 CFI pH 4.9 CFI pH 4.7 CFI
0 90.5 [25.7] 90.6 [17.6] 91.8 [25.8] 93.4 [19.1]
2.5 90.3 [24.7] 93.6 [20.3] 93.9 [15.6] 95.2 [26.0]
6 90.8 [20.5] 93.6 [21.1] 94.1 [24.0] 96.5 [27.0]
12 94.1 [27.8] 94.3 [27.1] 93.7 [22.5] 95.6 [26.5]
24 88.7 [22.0] 98.8 [36.2] 99.9 [27.9] 97.0 [26.3]
12.5 mg/mL CFI Formulations in 0.4% polysorbate 20 at pH 5.2, 4.9, and 4.7
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comparable to each other, but were significantly faster than for
the control CFI formulation without 0.4% polysorbate 20
(Fig. 2b and Table IV). However, the pH 4.7 CFI formulation
had an even faster IVR profile with most of its drug content
released within the first 30 min. At the end of the 4-h incubation
period, all of the formulations reached a plateau representing
~100% release of encapsulated drug.
The IVR profiles for the pH 5.2, 4.9, and 4.7 CFI formu-
lations containing 0.4% polysorbate 20 were assayed after
refrigerated storage for 6 months (Fig. 2c) and 1 year
(Fig. 2d). The IVR profiles for the CFI formulations contain-
ing 0.4% polysorbate 20 at pH 5.2, 4.9, and 4.7 were relatively
unchanged over this 1-year time frame with respect to their
“burst” values, indicative of the amount of encapsulated drug,
their rates of release (Table IV), and their plateau values,
which represented 100% release of encapsulated drug.
Aerosol Characterization
Initially, CFI formulations containing 0.4% polysor-
bate 20 were evaluated using various jet nebulizers to
characterize their aerosol performance. The presence of
the surfactant resulted in excessive foaming and led to
very low and inconsistent aerosol output rates thus ren-
dering jet nebulization inappropriate for use with these
formulations. A transition to a vibrating mesh nebulizer,
the PARI eFlow rapid, was then made. The aerosol
particle size distribution of the 12.5 mg/ml CFI prepara-
tion containing 0.4% polysorbate 20, pH-5.5, was deter-
mined after mesh nebulization with a VMD of 3.74 μm
(SD=0.01 μm, n=3) and a GSD of 1.72 (SD=0.02, n=3).
Aerosol Emitted Dose, and Effect on Vesicle Size
and Encapsulation State
Using the PARI eFlow rapid, 5 mL of each formulation
was nebulized ranging between 3.4 and 4.0 min, slightly faster
than that for the CFI control without surfactant (Table V).
The emitted dose (ED) values for the three experimental
formulations ranged between 57 and 61% of the dose loaded
in the nebulizer, lower than the ~72% ED observed for the
CFI Control (Table V). Given the shorter nebulization times,
it is not surprising that the ED values would be lower for the
experimental formulations. The lower ED values for the ex-
perimental formulations were likely a result of the small
amount of foam observed in the reservoirs which may have
reduced the formulation volume that was available to pass
through the mesh. The mass balance recovery exceeded 90%
on average. For all three experimental formulations, the mean
vesicle size increased by ~3 nm for the material recovered
from the nebulizer reservoir and by an additional ~30 nm for
the collected aerosol (Table V). This is in contrast to the
control CFI formulation for which there was no significant
change in mean vesicle size for either the nebulizer reservoir
or collected aerosol compartments (Table V). The encapsula-
tion state of formulation recovered from the nebulizer reser-
voir decreased significantly for all three formulations to
between 65 and 77% whereas the encapsulation state of the
control CFI formulation was unchanged (Table V).
One Month Analysis: Effect on Vesicle Size and Encapsulation
State
At the 1-month time point, the CFI formulations contain-
ing 0.4% polysorbate 20 at pH 5.2, 4.9, and 4.7 were aerosol-
ized but this time, instead of collecting the aerosol in the
BioSampler for subsequent analysis, aerosol droplets which
coalesced inside the mouthpiece were evaluated for vesicle
size and encapsulation state. This change was made in case the
BioSampler collection process was contributing to changes in
the state of the sample; e.g., the increase in vesicle size ob-
served in the aerosol samples at the initial time point. For all
three formulations, there was a small increase in the average
vesicle size for the residual solution in the nebulizer reservoir,
consistent with the initial assessment (Table VI). However, in
contrast to the previous results at time zero, there was no
additional increase in the vesicle size for the collected aerosol
samples for all three formulations (Table VI). This result
suggests that the BioSampler collection process was primarily
responsible for the increase in the vesicle size upon aerosoli-
zation, not the mesh nebulization process itself. The encapsu-
lation state for the formulation remaining in the nebulizer
reservoir did not decrease as significantly for any of the three
formulations as at the time zero analysis. However, the col-
lected aerosol samples all decreased to an encapsulation state
of between 70 and 80%, consistent with what was observed at
time zero using the BioSampler (Table V).
Six Month Analysis: Effect on Vesicle Size, Encapsulation State
and IVR Profile
At the 6 month time point, the effect of aerosolization of the
CFI formulations containing 0.4% polysorbate 20 at pH 5.2, 4.9,
Table II. The pH of the CFI Control and the pH Adjusted 12.5 mg/ml
CFI Formulations Containing 0.4% Polysorbate 20 After Refrigerated
Storage for 1, 6, 12 and 24 Months
Time (months) pH 5.2 CFI pH 4.9 CFI pH 4.7 CFI
0 5.18 4.91 4.67
1 5.14 4.89 4.63
6 4.88 4.82 4.61
12 5.05 4.93 4.71
24 5.05 5.02 4.85
12.5 mg/mL CFI formulations in 0.4% polysorbate 20 at pH 5.2, 4.9,
and 4.7
Table III. The Percent Encapsulation of Ciprofloxacin in the CFI
Control and in the pH Adjusted 12.5 mg/ml CFI Formulations Con-
taining 0.4% Polysorbate 20 After Refrigerated Storage for 1, 2.5, 6,











0 99.5 80.1 84.9 92.8
1 98.9 77.0 84.7 91.1
2.5 99.6 79.0 86.6 94.8
6 99.1 76.5 81.2 89.6
12 99.7 80.0 86.9 92.2
24 99.3 80.8 85.4 92.0
12.5 mg/mL CFI Formulations in 0.4% polysorbate 20 at pH 5.2, 4.9,
and 4.7
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and 4.7 was evaluated with respect to vesicle size, encapsulation
state, and IVR profile. For all three formulations, the mean
vesicle size increased by 2–3 nm for the sample recovered from
the nebulizer reservoir and by a further 1–3 nm for the collected
aerosol sample (Table VI), consistent with what was observed at
the 1-month time point. The encapsulation state decreased slight-
ly by 1 to 6% for all three formulations whether recovered from
the nebulizer reservoir or after aerosolization (Table VI).
After 6 months stability, the pH 4.7, 4.9, and 5.2 CFI
formulations were aerosolized and the collected aerosol and
the residual formulation in the nebulizer reservoir were eval-
uated in the IVR assay. The IVR profiles of the collected
aerosol samples were comparable to those for the residual
formulation remaining in the nebulizer reservoir (Fig. 2e).
The IVR profiles for the aerosolized pH 5.2 and 4.9 CFI
formulations containing 0.4% polysorbate 20 were also com-
parable to that for the unnebulized control samples at the 6-
month time point (Fig. 2c). However, for the pH 4.7 CFI
formulation containing 0.4% polysorbate 20, the IVR profiles
for both the collected aerosol and nebulizer reservoir samples
(Fig. 2e) did not show as rapid a release as for the unnebulized
control (Fig. 2c), but instead had IVR profiles that were
similar to the CFI formulations at higher pH.
Cryo-TEM Imaging
To examine if the physical structure of the liposomes was
altered by nebulization, cryo-TEM imaging was performed.
Cryo-TEM imaging of the control CFI without surfactant
reveals a population of spherical, unilamellar vesicles between
~50 and 100 nm in diameter (Fig. 3a), consistent with that
reported previously (15). Imaging was also performed on CFI
diluted with 0.4% polysorbate 20 and water, to produce tran-
sient osmotic swelling, and an increase in free drug (Fig. 3b).
The majority of these surfactant-associated liposomes looked
qualitatively similar to that for control CFI (Fig. 3b vs. 3a);
however, there was a minority of liposomes that were lighter,
consistent with loss of encapsulated drug (6). Cryo-TEM imag-
ing was not performed on the pH adjusted CFI formulations.
After exposure of the 12.5 mg/ml CFI formulation containing
0.4% polysorbate 20 at pH 5.5 to the mesh nebulization process,
the aerosol sample recovered in the mouthpiece was not com-
promised with respect to the liposome structure or integrity as
evidenced by cryo-TEM analysis (Fig. 3c). There was no notice-
able change in the size distribution of the liposomes or an
increase in the proportion of liposomes with lighter shading,
which would have suggested loss of encapsulated drug. There
Table IV. The Normalized Rate of Release in the IVR Assay of the pH Adjusted 12.5 mg/mL CFI Formulations Containing 0.4% Polysorbate
20 After Refrigerated Storage for 1, 6, and 12 Months. The Initial Rate of Release in the IVR Assay is Defined as 100×(T30−T0)/(T240−T0) was
Normalized by Dividing by the Initial Rate of Release of the CFI Control at the Same Time Point and Expressed as a Percentage
Formulation
Normalized IVR (%) Relative IVR (% of control CFI)
Time (months) Time (months)
1 6 12 1 6 12
Control CFI 47.0 42.8 40.1 100 100 100
pH 5.5 CFI 55.7 ND ND 118 ND ND
pH 5.2 CFI 60.9 50.6 54.7 129 118 136
pH 4.9 CFI 64.3 52.2 58.9 137 122 147
pH 4.7 CFI 86.1 100.1 97.5 183 234 243
12.5 mg/mL CFI Formulations in 0.4% polysorbate 20 at pH 5.5, 5.2, 4.9, and 4.7. The normalized IVR equals=100×(T30min−T0min)/(T240min–
T0min). The relative IVR=100×(normalized IVRSAMPLE/normalized IVRCONTROL)
ND not done
Table V. Characterization of the Effect of Nebulization of the CFI Control and pH Adjusted 12.5 mg/ml CFI Formulations Containing 0.4%
Polysorbate 20. The Vesicle Size Data are Reported as the Mean (in nm) and [SD]. The State of Ciprofloxacin Encapsulation is Reported in
Terms of Percentage. The Percent Recovery of Ciprofloxacin in the Nebulizer Reservoir and in the Collected Aerosol (emitted dose) Allows for



















CFI control #1 90.5 [25.7] 91.6 [22.9] 91.3 [22.7] 99.5 98.9 21.6 73.2 94.8 5.0
#2 90.5 [25.7] 89.9 [22.3] 90.8 [25.9] 99.5 99.0 23.6 71.2 94.8 4.2
pH 5.5 CFI #1 90.6 [17.6] 92.1 [24.9] 127.9 [77.6] 70.2 67.6 34.9 58.2 93.1 3.5
#2 90.6 [17.6] 94.7 [23.2] 135.0 [85.0] 70.2 65.6 33.2 60.3 93.5 4.0
pH 5.2 CFI ND ND ND ND 80.1 ND ND ND ND ND
pH 4.9 CFI #1 91.8 [25.4] 94.8 [28.1] 128.7 [76.6] 84.9 70.5 30.5 61.0 91.5 3.7
#2 91.8 [25.4] 94.6 [29.0] 125.3 [74.5] 84.9 73.4 33.8 57.2 91.0 3.4
pH 4.7 CFI #1 93.4 [19.1] 96.2 [26.0] 125.9 [73.0] 92.8 77.0 30.6 59.1 89.8 3.9
#2 93.4 [19.1] 96.3 [25.8] 123.1 [72.7] 92.8 73.7 33.3 59.5 92.8 3.6
ND not done, Neb nebulization, Neb. Res. nebulizer reservoir solution
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was also no evidence of deformed liposomes or liposomal de-
bris, which might be indicative of vesicle rupture during the
mesh nebulization process.
DISCUSSION
We have investigated the interaction of polysorbate 20
with a liposomal ciprofloxacin formulation with the goal to
develop novel formulations with modified encapsulation states
and release properties which could then be used in nebulizers.
Our strategy was to mix polysorbate 20 with the liposomes, in
conjunction with osmotic swelling, so that the liposome vesicles
retain their integrity, but have altered drug release rates (6). The
amount of unencapsulated ciprofloxacin increased with great-
er concentrations of surfactant (Fig. 1) and above 0.4% poly-
sorbate 20 there was a more rapid release profile in the IVR
assay (Fig. 2a). The encapsulation states of the CFI formula-
tions containing polysorbate 20 were maintained on long-term
stability (Table III) which supports the model that sublytic
concentrations of surfactant form transient pores in liposome
bilayers allowing release of some of the encapsulated drug
before the membrane barrier is fully recovered (20,21). These
liposomes might then be expected to maintain their structural
integrity for prolonged time periods as was observed in our 2-
year stability study. The cryo-TEM micrographs of mixtures
of CFI and low levels of polysorbate 20 are practically indis-
tinguishable from CFI alone (Figs. 3a, b). The micrographs
show predominantly spherical, unilamellar liposomes between
around 50 and 100 nm for the control CFI liposomes, as well
as for the surfactant-associated liposomes prior to and after
mesh nebulization (Fig. 3c).
Because ciprofloxacin is poorly soluble at neutral pH, the
external pH of the surfactant-liposome mixture was reduced
to 5.2, 4.9, and 4.7 to improve the likelihood that the released
ciprofloxacin would remain in solution during long-term re-
frigerated storage. The pH 4.7 and 4.9 preparations retained
good appearance after 2-year refrigerated storage in contrast
to the pH 5.5 preparation which formed ciprofloxacin crystals
within 48 h. The appearance of the pH 5.2 preparation showed
some small particulates but otherwise showed no further
deterioration after 24 months refrigerated storage. The inten-
tional reduction in pH in these CFI formulations was associ-
ated with an increase in encapsulation relative to the pH 5.5
formulation, with the greatest encapsulation for the lowest pH
CFI formulation (Table III). Because acetate buffer was used
to lower the pH for the pH modified formulations, in place of
some of the dilution water, the external environment would be
less hypotonic. This observation may explain the higher levels
of drug encapsulation for the lower pH formulations. Notably
however, once this new encapsulation state was established, it
did not fluctuate during the course of the 2-year refrigerated
storage (Table III). Use of acetic acid, instead of acetate
buffer, to perform the dilutions could be used in the future
to reduce the pH while maintaining a more hypotonic envi-
ronment so that the encapsulation state could be reduced
further, similar to the levels for the pH 5.5 CFI formulation.
There was also a slight increase in vesicle size with reduc-
tion in pH upon preparation but there were no further vesicle
size changes throughout the course of the 2-year refrigerated
storage (Table II). The IVR profiles for the liposome-surfac-
tant preparations at pH 5.2 and 4.9 were similar to that for the
pH 5.5 preparation (Fig. 2b), and retained that modified re-
lease profile through 12 months refrigerated storage
(Fig. 2c, d). In contrast, the pH 4.7 surfactant-liposome prep-
aration had a much faster release profile in the IVR assay
(Fig. 2b) that remained unchanged after 1-year refrigerated
storage (Fig. 2c, d). It is unclear why the lowest pH liposome-
surfactant preparation had an even faster release rate but it
may be related to changes in the transmembrane pH gradient
which is used to load the drug during manufacture of the
liposomes (17,18).
Many liposomal products have been developed with the
intention for inhalation administration to treat lung disease
(2). However, very few have been found to be robust to the
nebulization process (2). Liposomes containing surfactant
have historically been even less stable than traditional lipo-
somes in response to nebulization with changes in vesicle size
or encapsulation (14,22). Ultradeformable liposome formula-
tions containing salbutamol sulfate and comprised of soy
phosphatidylcholine (PC), polysorbate 80, and cholesterol
Table VI. The Liposome Vesicle Size Distribution and the Percent Encapsulation of Ciprofloxacin After 1 and 6 Months Refrigerated Storage
and Following Nebulization for the pH Adjusted 12.5 mg/ml CFI Formulations Containing 0.4% Polysorbate 20. Vesicle Size Data are Reported
as the Mean (in nm) and [SD]. Duplicate Nebulization Experiments were Performed at the 1-Month Time Point Versus Single Experiments at
the Six-Month Time Point
Formulation Expt. run
Mean vesicle size (nm) [SD] Encapsulation (%)
Before Neb. Neb. Res. Aerosol Before Neb. Neb. Res. Aerosol
1-month analysis
pH 5.2 CFI #1 91.1 [19.7] 90.8 [24.2] 92.6 [32.0] 76.6 76.6 74.8
#2 91.1 [19.7] 95.2 [16.7] 95.8 [32.2] 76.6 77.0 73.1
pH 4.9 CFI #1 91.8 [25.3] 93.0 [24.4] 93.1 [33.7] 85.2 82.8 73.4
#2 91.8 [25.3] 94.1 [26.9] 94.7 [29.7] 85.2 82.4 79.0
pH 4.7 CFI #1 95.4 [27.4] 96.7 [23.6] 96.2 [27.9] 92.6 89.8 71.7
#2 95.4 [27.4] 99.3 [27.5] 99.7 [30.8] 92.6 89.1 81.2
6-month analysis
pH 5.2 CFI 93.6 [21.1] 96.0 [23.8] 99.0 [29.2] 76.5 70.7 76.5
pH 4.9 CFI 94.1 [24.0] 96.5 [24.7] 97.6 [29.8] 81.2 75.7 77.2
pH 4.7 CFI 96.5 [27.0] 98.6 [23.1] 101.2 [34.2] 89.6 85.4 84.9
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were evaluated in jet, ultrasonic, and mesh nebulizers and all
combinations were found to have marked losses in drug
encapsulation and changes in vesicle size (14). Liposomes
containing cyclosporine and comprised of soy PC and polysor-
bate 80 were exposed to mesh nebulization and the average
vesicle size doubled from 51 nm before nebulization to 107 nm
after nebulization (22). However, there was no reported loss
in drug encapsulation, presumably because the poorly soluble
cyclosporine drug remained associated with the hydrophobic
liposome bilayers (23). Specially designed liposomal ciproflox-
acin formulations have already been shown to be stable to jet
nebulization with no meaningful changes in vesicle size or loss
in drug encapsulation (19,24). After mesh nebulization, sur-
factant-associated liposomal ciprofloxacin formulations (con-
taining 0.4% polysorbate 20) showed a small increase in mean
vesicle size (by a few nm) and the drug encapsulation also
decreased to 70–85% (Table VI). However, the degree of
modification to these surfactant-associated liposomal cipro-
floxacin formulations is less pronounced than for those lipo-
somal formulations discussed above (14,22).
Liposomal ciprofloxacin formulations containing 0.4%
polysorbate 20 possessed modified release properties
(Fig. 2a), yet were found to retain those IVR characteristics
after 12 months refrigerated storage (Fig. 2d). In addition,
after 6 months storage followed by mesh nebulization, all
formulations demonstrated relatively comparable encapsula-
tion states and IVR profiles (Fig. 2e). One unexplained find-
ing related to this observation is why the pH 4.7 CFI
preparation, with the most rapid IVR profile prior to nebuli-
zation (Fig. 2c), has an IVR profile comparable to those for
the pH 4.9 and 5.2 preparations after mesh nebulization
(Fig. 2e). While no explanation is evident, this result suggests
that the mesh nebulization process has an effect on the low pH
CFI formulation, even if that effect was only to make its IVR
profile similar to that of the higher pH CFI formulations.
Another interesting observation is that this change in IVR
profile occurred not only for the collected aerosol sample
which passed through the mesh, but also for the residual
formulation remaining in the reservoir, upstream of the mesh.
This phenomenon of alteration to a liposomal formulation
upstream of the mesh (in addition to modification to the
formulation which passed through the mesh), due to the en-
ergetics of the vibrating mesh, has been reported previously
(2). Similar to our data for the pH=4.7 formulation, liposomal
formulations of salbutamol sulfate showed changes in vesicle
size (14) and encapsulation (14,25) for the residual formula-
tions in the nebulizer reservoirs.
CONCLUSIONS
We have demonstrated that the encapsulation state and
IVR properties of a liposomal ciprofloxacin formulation,
12.5 mg/ml CFI containing 0.4% polysorbate 20, could be
modified post manufacture by the addition of surfactant while
still retaining acceptable long-term stability when formulated
between a pH of 4.7 and 5.2. These modified formulations
were nebulized using a vibrating mesh device to produce
aerosols in the respirable size range, appropriate for delivery
to the airways to treat lung disease. While there were small
changes in the encapsulation state and vesicle size following
mesh nebulization, these formulations retained a faster IVR
profile than for the unmodified CFI control formulation. Fu-
ture research efforts will focus on how the changes observed in
Fig. 3. Cryo-TEM micrographs of various preparations of liposomal
ciprofloxacin. The scale bar in the bottom left-hand corner of each
micrograph is 100 nm for a, b, and c. All samples were applied at a
concentration of ~10 mg/mL liposomes. a 12.5 mg/ml CFI; b 12.5 mg/
ml CFI in 0.4% polysorbate 20, pH 5.5; and c 12.5 mg/ml CFI in 0.4%
polysorbate 20, pH 5.5, after mesh nebulization
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the in vitro release rate translate in the in vivo setting. It may
be possible one day to personalize inhaled therapy of liposo-
mal formulations by selecting a surfactant, at a specified con-
centration, pH, and osmolarity, to achieve a specific, desired
change in encapsulation state and/or IVR properties for a
specific individual.
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